索拉非尼相关手足皮肤反应的研究进展

Researchprogress of sorafenib associated hand-foot skin reactions

甲苯磺酸索拉非尼是一种口服多激酶抑制剂,自2005年12月获得FDA批准以来,已成为无法切除的肝细胞癌的一线治疗药物。索拉非尼已被证实具有较好的安全性,但是手足皮肤反应作为其最常见的不良反应,虽然不危及生命,但可导致药物剂量改变或中断用药,从而限制抗肿瘤作用。本文就索拉非尼引起手足皮肤反应的临床特征、发病机制、预防及患者管理策略等进行综述,以期为该不良反应的临床管理和防治提供参考,提高患者用药依从性和抗肿瘤效果。

Sorafenib tosylate is a multikinase inhibitor that has been approved by the FDA since December 2005.It has become a first-line in the treatment unresectable hepatocellular carcinoma.It has been proved to have good safety.But as the most common adverse reaction, although HFSR is not life-threatening, it may lead to dose change or interruption, thereby limiting the anti-tumor effect.In this paper, the clinical characteristics, pathogenesis, prevention and management of HFSR induced by sorafenib were reviewed.In order to provide reference for the clinical management and prevention of this adverse reaction, improve the drug compliance and anti-tumor effect of patients.